Archives
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2018-07
-
Controlling Lipid Nanoparticle Size to Optimize mRNA Deliver
2026-05-22
This study reveals how precise adjustments to manufacturing parameters can tailor lipid nanoparticle (LNP) dimensions, directly influencing mRNA delivery efficiency and expression outcomes both in vitro and in vivo. The findings have broad implications for the design of LNP-based mRNA therapeutics and reporter assays, highlighting the importance of nanoparticle size control in translational research.
-
METTL14 Controls Colonic Inflammation via m6A-LncRNA Axis in
2026-05-21
This study uncovers how METTL14-mediated m6A modification of lncRNA DHRS4-AS1 regulates inflammation in ulcerative colitis via the miR-206/A3AR axis. The findings highlight a novel epigenetic mechanism for controlling inflammatory injury in colonic tissue, offering potential new therapeutic targets.
-
Repurposing Sulfasalazine for Sarcopenia: Insights from In V
2026-05-21
This article examines a recent study that identifies sulfasalazine, traditionally used for inflammatory bowel disease, as a candidate for sarcopenia therapy by targeting the PHF20-YY1 axis in muscle cells. The findings demonstrate the value of drug repositioning screening using FDA-approved compound libraries for uncovering novel therapeutic strategies in muscle-wasting conditions.
-
Cefepime (BMY-28142): Breakthroughs in Adaptive Resistance M
2026-05-20
Explore how Cefepime (BMY-28142) enables advanced adaptive resistance modeling in central nervous system infection research. This article offers new insights into PKPD approaches and practical assay design, setting it apart from existing analyses.
-
2'3'-cGAMP (sodium salt): Applied Insights for STING Pathway
2026-05-20
2'3'-cGAMP (sodium salt) from APExBIO is a high-affinity, water-soluble tool that enables precise interrogation of the cGAS-STING pathway in immunology, oncology, and antiviral workflows. This article delivers practical guidance on experimental design, troubleshooting, and leveraging recent mechanistic findings for next-level assay reproducibility.
-
Neurotensin: Precision Tool for Neurotensin Receptor 1 Activ
2026-05-19
Neurotensin (CAS 39379-15-2) stands apart as a validated 13-amino acid neuropeptide enabling high-fidelity studies of GPCR trafficking mechanism and miRNA regulation in gastrointestinal and neural models. By leveraging its unmatched purity and mechanistic specificity, researchers can dissect receptor recycling and intracellular signaling with reproducible precision—even in complex, interference-prone assay environments.
-
iRhom2 Regulates Olfactory Receptor Dynamics and Sensory Ada
2026-05-19
This study uncovers the selective role of iRhom2 in olfactory sensory neurons, revealing its impact on odorant receptor gene regulation and activity-dependent adaptation. The findings establish a feedback loop linking odor exposure, iRhom2 expression, and olfactory receptor repertoire, with implications for sensory plasticity.
-
Sisomicin: Optimizing Aminoglycoside Antibiotic Workflows
2026-05-18
Sisomicin empowers infection research with robust, reproducible inhibition of both Gram-negative and Gram-positive pathogens. Discover how advanced protocol design, precise dosing, and troubleshooting with Sisomicin can elevate antibacterial assays beyond classic aminoglycoside standards.
-
Applied Workflows with PPT (Propyl Pyrazole Triol) in ERα Si
2026-05-18
PPT (Propyl Pyrazole Triol) stands out as a highly selective ERα agonist, driving precision and reproducibility in estrogen receptor research. Explore best practices, advanced experimental designs, and actionable troubleshooting insights for maximizing ERα-mediated gene expression studies, informed by the latest biomarker-driven findings.
-
LC–MS/MS Reveals GS-441524 Prodrug Conversion Pathways In Vi
2026-05-17
This study introduces and characterizes a novel GS-441524 prodrug (NGP-1) with enhanced oral bioavailability for anti-SARS-CoV-2 therapy. Using advanced LC–MS/MS analytics, the research maps the stepwise conversion of NGP-1 to its active metabolite in vitro and in vivo, informing both drug mechanism understanding and pharmacokinetic optimization.
-
5-hme-dCTP: Enabling Precision DNA Hydroxymethylation Assays
2026-05-16
5-hme-dCTP (5-Hydroxymethyl-2’-deoxycytidine-5’-Triphosphate) empowers researchers to map and manipulate DNA hydroxymethylation with unprecedented specificity, particularly for plant stress epigenetics. This guide delivers optimized protocols, workflow enhancements, and troubleshooting insights for maximizing data quality in gene regulation studies.
-
N1-Methyl-Pseudouridine-5'-Triphosphate: Precision RNA Engin
2026-05-15
Explore how N1-Methyl-Pseudouridine-5'-Triphosphate enhances RNA stability and fidelity for advanced mRNA therapeutics and research. This in-depth article reveals unique insights into translational accuracy, protocol parameters, and critical findings from landmark studies.
-
Deferasirox in Ferroptosis Modulation: Mechanistic Insights
2026-05-15
Explore how Deferasirox, a leading oral iron chelator, uniquely modulates ferroptosis and iron metabolism in cancer research. This article delivers a deep mechanistic analysis and protocol guidance, setting it apart from existing overviews.
-
BI 2536 (SKU A3965): Advancing PLK1 Inhibition in Cancer Res
2026-05-14
This article addresses key experimental challenges in cell cycle and apoptosis assays, demonstrating how BI 2536 (SKU A3965) from APExBIO provides robust, reproducible solutions for cancer research. Evidence-based scenario Q&As highlight its specificity, practical handling, and data-backed performance advantages.
-
Selective Inhibition of Aminopeptidases and ACE: Insights fo
2026-05-14
This study re-evaluates the selectivity of widely used metallopeptidase inhibitors, focusing on their actions against aminopeptidases N, A, and W, as well as angiotensin converting enzyme (ACE). The findings clarify inhibitor specificity, which is critical for designing precise experiments in cardiovascular and peptide metabolism research.